Black Henry R, Keck Michael, Meredith Peter, Bullen Kevin, Quinn Sheila, Koren Andrew
Rush-Presbyterian-St. Luke's Medical Center, Chicago, IL 60612, USA.
J Clin Hypertens (Greenwich). 2006 Mar;8(3):159-66; quiz 167-8. doi: 10.1111/j.1524-6175.2006.04811.x.
Doxazosin gastrointestinal therapeutic system (GITS) or placebo was added to the antihypertensive therapy of uncontrolled hypertensive patients in a prospective, randomized, double-blind trial. Patients received doxazosin GITS 4 mg/d (n=89) or placebo (n=86) for 6 weeks in addition to entry antihypertensive medication. Doxazosin GITS was increased to 8 mg/d after 2 or 4 weeks if patients did not respond (sitting blood pressure <140/90 mm Hg and 10/10-mm Hg decrease from baseline). Reductions from baseline in sitting and standing blood pressures were greater with doxazosin GITS than placebo at all time points (p</=0.017) except Week 1 sitting systolic pressure (p=0.068). The response rate was greater in the doxazosin GITS group (37.3%) than the placebo group (10.7%; p<0.001). With the exception of postural hypotension (7% compared with 0.0%), the frequency of adverse events was similar for doxazosin GITS and placebo. Doxazosin GITS was effective as combination antihypertensive therapy with the major classes of antihypertensive agents.
在一项前瞻性、随机、双盲试验中，将多沙唑嗪胃肠道治疗系统（GITS）或安慰剂添加到血压控制不佳的高血压患者的抗高血压治疗中。患者除了服用初始抗高血压药物外，还接受多沙唑嗪GITS 4毫克/天（n = 89）或安慰剂（n = 86）治疗6周。如果患者没有反应（坐位血压<140/90毫米汞柱且比基线降低10/10毫米汞柱），2周或4周后将多沙唑嗪GITS增加至8毫克/天。在所有时间点，多沙唑嗪GITS组的坐位和立位血压较基线的降幅均大于安慰剂组（p≤0.017），但第1周坐位收缩压除外（p = 0.068）。多沙唑嗪GITS组的有效率（37.3%）高于安慰剂组（10.7%；p<0.001）。除体位性低血压外（7% 对比0.0%），多沙唑嗪GITS和安慰剂的不良事件发生率相似。多沙唑嗪GITS作为与主要抗高血压药物类别联合使用的抗高血压治疗有效。
